|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Tumor Biology |
Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
2 Address correspondence and reprint requests to Shingo Takano, M.D., Ph.D., Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Ibaraki 305-8575, Japan.
Abstract
We evaluated the effectiveness of vascular endothelial growth factor (VEGF) blockade alone and in combination with 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU, nimustine), a cytotoxic agent commonly used in the treatment of malignant gliomas, to eradicate tumors of human glioblastoma cell lines implanted in SCID (severe combined immunodeficiency) mice. ACNU, but not cisplatin and etoposide, elevated VEGF expression in a glioma cell line in vitro. VEGF antibody alone inhibited glioma growth in vivo as a result of angiogenesis inhibition. The combination with ACNU resulted in an additive effect for inhibition of glioma growth. ACNU also induced VEGF up-regulation in glioma tissues, which was decreased with VEGF antibody treatment. One of the mechanisms of the additive effect of the VEGF antibody and ACNU combination is the blockade of VEGF up-regulation induced by ACNU. As such, the combination of antiangiogenic therapy with conventional therapy is promising for glioma treatment in the future.
References
Ando, S., Nojima, K., Ishihara, H., Suzuki, M., Ando, M., Majima, H., Ando, K., and Kuriyama, T. (2000) Induction by carbon-ion irradiation of the expression of vascular endothelial growth factor in lung carcinoma cells. Int. J. Radiat. Biol. 76,1121 -1127.[CrossRef][Medline]
Asano, M., Yukita, A., Matsumoto, T., Hnatani, M., and Suzuki, H. (1998) An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 17,185 -190.[Web of Science][Medline]
Asano, M., Yukita, A., and Suzuki, H. (1999) Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn. J. Cancer Res. 90,93 -100.[CrossRef][Web of Science][Medline]
Bernsen, H.J.J.A., Risked, P.F.J.W., Peters, J.P.W., Bakker, H., and van der Kogel, A.J. (1998) Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery 43,570 -576.[Medline]
Borgstrom, P., Gold, D.P., Hillan, K.J., and Ferrara, N. (1999) Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19,4203 -4214.[Web of Science][Medline]
Brem, S., Cotran, R., and Folkman, J. (1972) Tumor angiogenesis: A quantitative method for histologic grading. J. Natl. Cancer Inst. 48,347 -356.
Cheng, S.Y., Huang, H.J., Nagane, M., Ji, X.D., Wang, D., Shih,
C.C.Y., Arap, W., Huang, C.M., and Cavenee, W.K. (1996)
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of
endogenous expression of vascular endothelial growth factor. Proc.
Natl. Acad. Sci. U.S.A. 93,8502
-8507.
Gordon, M.S., Margolin, K., Talpaz, M., Sledge, G.W., Jr.,
Holmgren, E., Benjamin, R., Stalter, S., Shak, S., and Adelman, D.C.
(2001) Phase I safety and pharmacokinetic study of recombinant
human anti-vascular endothelial growth factor in patients with advanced
cancer. J. Clin. Oncol.
19,843
-850.
Gorski, D.H., Beckett, M.A., Jaskowiak, N.T., Calvin, D.P.,
Mauceri, H.J., Salloum, R.M., Seetharam, S., Koons, A., Hari, D.M., Kufe.,
D.W., and Weichselbaum, R.R. (1999) Blockade of the vascular
endothelial growth factor stress response increases the antitumor effects of
ionizing radiation. Cancer Res.
59,3374
-3378.
Jensen, R.L. (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg. Neurol. 49,189 -196.[CrossRef][Web of Science][Medline]
Johansson, M., Bergenheim, A.T., Widmark, A., and Henriksson, R. (1999) Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br. J. Cancer 80,142 -148.[CrossRef][Medline]
Kendall, R.L., and Thomas, K.A. (1993) Inhibition of
vascular endothelial growth factor activity by an endogenously encoded soluble
receptor. Proc. Natl. Acad. Sci. U.S.A.
90,10705
-10709.
Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362,841 -844.[CrossRef][Medline]
Kirsch, M., Strasser, J., Allende, R., Bello, L., Zhang, J., and
Black, P.M. (1998) Angiostatin suppresses malignant glioma growth
in vivo. Cancer Res. 58,4654
-4659.
Lund, E.L., Spang-Thomsen, M., Skovgaard-Poulsen, H., and Kristjansen, P.E.G. (1998) Tumor angiogenesis: A new therapeutic target in gliomas. Acta Neurol. Scand. 97, 52-62.[Medline]
Lund, E.L., Bastholm, L., and Kristjansen, P.E.G.
(2000) Therapeutic synergy of TNP-470 and ionizing
radiation—Effects on tumor growth, vessel morphology, and angiogenesis
in human glioblastoma multiforme xenografts. Clin. Cancer
Res. 6,971
-978.
Margolin, K., Gordon, M.S., Holmgren, E., Gaudreault, J., Novothy,
W., Fyfe, G., Adelman, D., Stalter, S., and Breed, J. (2001)
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to
vascular endothelial growth factor in combination with chemotherapy in
patients with advanced cancer: Pharmacologic and long-term safety data.
J. Clin. Oncol. 19,851
-856.
Mauceri, H.J., Hanna, N.N., Beckett, M.A., Gorski, D.H., Staba, M.J., Stellato, K.A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G.A., Sukhatme, V.P., Kufe, D.W., and Weichselbaum, R.R. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.) 394,287 -291.[CrossRef][Medline]
Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W.,
Ullrich, A., and Strawn, L.M. (1996) Dominant-negative inhibition
of Flk-1 suppresses the growth of many tumor types in vivo. Cancer
Res. 56,1615
-1620.
Reijneveld, J.C., Voest, E.E., and Taphoorn, M.J.B. (2000) Angiogenesis in malignant primary and metastatic brain tumors. J. Neurol. 247,597 -608.[CrossRef][Web of Science][Medline]
Takakura, K., Abe, H., Tanaka, R., Kitamura, K., Miwa, T., Takeuchi, K., Yamamoto, S., Kageyama, N., Handa, H., Mogami, H., Nishimoto, A., Uozumi, T., Matsutani, M., and Nomura, K. (1986) Effects of ACNU and radiotherapy on malignant glioma. J. Neurosurg. 64,53 -57.[Web of Science][Medline]
Takano, S., Yoshii, Y., and Nose, T. (1991a) Ultrastructure of glioma vessel— morphometric study for vascular permeability (Japanese). No To Shinkei 43, 49-56.[Medline]
Takano, S., Yoshii, Y., and Nose, T. (1991b) Ultrastructure of glioma vessel-morphometric study for proliferative potential of endothelial cell (Japanese). No To Shinkei 43,145 -152.[Medline]
Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai,
S., and Nose, T. (1996) Concentration of vascular endothelial
growth factor in the serum and tumor tissue of brain tumor patients.
Cancer Res. 56,2185
-2190.
Takano, S., Tsuboi, K., Tomono, Y., Mistui, Y., and Nose, T. (2000) Tissue factor, osteopontin, avß3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer 82,1967 -1973.[CrossRef][Web of Science][Medline]
Teicher, B.A., Holden, S.A., Ara, G., Sotomayor, E.A., Huang, Z.D., Chen, Y.N., and Brem, H. (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer 57,920 -925.[Web of Science][Medline]
Wikstrand, C.J., Cokgor, I., Sampson, J.H., and Bigner, D.D. (1999) Monoclonal antibody therapy of human gliomas: Current status and future approaches. Cancer Metastasis Rev. 18,451 -464.[CrossRef][Web of Science][Medline]
Yoshida, J.A., Kajita, T., Wakabayashi, T., and Sugita, K. (1994). Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. (Wien) 127,55 -59.[CrossRef][Medline]
Yuan, F., Chen, Y.I., Dellian, M., Safabakhsh, N., Ferrara, F., and
Jain, R.K. (1996) Time-dependent vascular regression and
permeability changes in established human tumor xenografts induced by
anti-vascular endothelial growth factor/vascular permeability factor antibody.
Proc. Natl. Acad. Sci. U.S.A.
93,14765
-14770.
Zagzag, D. (1995) Angiogenic growth factors in neural embryogensis and neoplasia. Am. J. Pathol. 146,293 -309.[Abstract]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Martinez, E. Zudaire, S. Portal-Nunez, L. Guedez, S. K. Libutti, W. G. Stetler-Stevenson, and F. Cuttitta Proadrenomedullin NH2-Terminal 20 Peptide Is a Potent Angiogenic Factor, and Its Inhibition Results in Reduction of Tumor Growth Cancer Res., September 15, 2004; 64(18): 6489 - 6494. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
